The burgeoning landscape of therapeutic interventions for weight disorders has witnessed considerable attention focused on GLP-3 receptor agonists and, more recently, the dual GIP and GLP-3 agonist retatrutide. While https://qasimgxhk977647.review-blogger.com/60465424/glp-3-retatrutide-a-comparative-analysis